Pairs with the Market-Entry Gambit Canvas — a ready-to-use strategy tool. Included with a subscription, or $1.99.
On March 13, 2020, while the world was learning to spell 'PCR,' the FDA cleared Thermo Fisher's TaqPath COVID-19 test for emergency use.1 Within months the company was running one of the largest testing supply lines on earth, and the money arrived like a flood: by the fourth quarter of 2020 alone, COVID response was generating $3.2 billion in a single three-month stretch.2 Over the next year that line swelled to $9.23 billion.3 Then it evaporated - down to $330 million by 2023.8 A windfall that size, gone that fast, should leave a crater. It barely left a mark.
The obvious story is a boom and bust: Thermo Fisher rode the pandemic, made a fortune in test kits, and then watched the gravy train leave. That framing gets the facts right and the strategy exactly backwards. The boom was never the bet. What Thermo Fisher did with the cash was the bet - and the bust was the proof it had been placed correctly.
The windfall was treated as fuel, not as a business
Most companies that stumble into a temporary gold mine make the same mistake: they confuse the gold with a destiny. They expand capacity, hire to the peak, model the spike as a plateau, and build a cost base that assumes the river never runs dry. Thermo Fisher did the opposite. It read its COVID revenue as exactly what it was - a transient, high-margin flood of cash - and spent that cash on something permanent. On April 15, 2021, with testing revenue still climbing, it agreed to buy the contract research organization PPD for a $17.4 billion equity purchase price, $47.50 a share, plus the assumption of roughly $3.5 billion in net debt.4 PPD runs clinical trials for pharmaceutical companies. It has nothing to do with diagnostic testing and everything to do with where Thermo Fisher wanted to live: deep inside the drug-development pipeline of its largest customers.
“We've reached an important milestone in completing the acquisition of PPD.”5
The deal closed on December 8, 2021 - not, as the tidy retellings have it, in the dying days of the year, but with three weeks of runway to spare.5 The timing is the whole point. Thermo Fisher converted a one-time pandemic surge into a durable position in pharma services at the precise moment the surge was at its richest. It cashed a temporary check and bought a permanent seat.
| The trap most fall into | What Thermo Fisher did | |
|---|---|---|
| Reads the spike as | A new plateau | A transient flood |
| Spends the cash on | More of the spiking thing | A permanent, unrelated platform |
| Cost base after the bust | Built for the peak, now stranded | Unchanged by the testing line |
| When demand collapses | Existential crisis | A rounding error |
Why a $6 billion haircut barely showed up
Here is the mechanism that makes the bust a non-event. When COVID testing fell from $9.23 billion in 2021 to $3.11 billion in 2022 - a two-thirds drop - total company revenue did not fall. It rose roughly 15%, to $44.92 billion.6 The rest of the business, fattened by PPD and by years of underlying demand from pharmaceutical and biotech customers, grew faster than testing shrank. By 2023, when testing dwindled to $330 million for the full year and a mere $50 million in the final quarter, total revenue declined only 5%, to $42.86 billion.8 Strip out the pandemic line entirely and the core business kept compounding. The company had already told investors how the wind-down would go: in May 2022 the CFO guided to an 'endemic run-rate' of about $100 million a quarter in the back half of the year, treating the collapse not as a shock to be managed but as a known glide path.7
That is the tell. A company genuinely dependent on a windfall does not absorb a multi-billion-dollar revenue reversal and keep its top line within a few points of flat. The COVID line was a guest, not a tenant. When it left, the house was full of people who pay rent every month - the pharmaceutical companies whose trials, instruments, and supply chains Thermo Fisher had spent the windfall getting closer to.
Wasn't this just luck dressed up as foresight?
The honest objection is that Thermo Fisher got lucky twice and called it strategy. Lucky once when a pandemic happened to need exactly the testing infrastructure it already had; lucky again that PPD turned out to be a good asset bought with house money. There is truth in it. The TaqPath authorization was timing, not genius, and any large diagnostics player would have caught some of the same wave. But luck explains the inflow, not the deployment - and the deployment is what separates Thermo Fisher from every firm that booked record pandemic quarters and then had nothing to show once the demand vanished. The discipline was in refusing to mistake the spike for the company. Plenty of testing-boom winners are now smaller than they were in 2021. Thermo Fisher is structurally larger, and the new mass sits in clinical trials, not swabs. Luck handed it the chips. The choice was to push them onto a different table entirely.
When a one-time surge floods your business - a viral hit, a regulatory tailwind, a pandemic - the dangerous instinct is to build for the peak: more capacity, more headcount, a cost base that assumes the river keeps running. The disciplined move is to treat transient cash as fuel for a permanent position you'd want regardless. Convert the spike into a durable asset that compounds after the spike is gone. The test is simple and brutal: when the windfall reverses - and it always reverses - does your top line crater, or does it barely notice? If the answer is 'barely,' you spent the money on a business. If it's 'crater,' you mistook the weather for the climate.
The COVID testing line peaked at $9.23 billion and faded to a rounding error in three years, and almost nobody who follows Thermo Fisher would call it a crisis. That is the strange verdict of the whole episode: the most consequential thing about the boom was not how big it got, but how little its ending mattered. Thermo Fisher caught a wave it never needed, rode it precisely as long as it lasted, and spent every dollar building the boat. When the water went out, the boat was still there - and it was the boat that was always the point.
Market-Entry Gambit Canvas
A one-page canvas for staging an entry into a market you don't own yet: the beachhead you take first, the wedge that gets you in cheaply, the sequence that turns a foothold into a position, and the incumbent's likely counter-move. Blank to plan your own entry; filled as the worked example showing how the story's challenger picked its landing spot and walked the rest in.
Included with any subscription, or unlock this tool for $1.99. Get it → · See plans →
Sources
Where this comes from — the filings, records, and reporting behind it.
- 1Thermo Fisher's TaqPath COVID-19 Combo Kit received FDA Emergency Use Authorization on March 13, 2020.
- 2Full-year 2020 revenue grew 26% to $32.22 billion; Q4 2020 alone generated $3.2 billion of COVID-19 response revenue.
- 3Full-year 2021 revenue grew 22% to $39.21 billion; COVID-19 response revenue for full-year 2021 was $9.23 billion.
- 4Thermo Fisher agreed to acquire PPD for $47.50/share, a total equity purchase price of $17.4 billion plus assumption of ~$3.5 billion of net debt; the deal was announced April 15, 2021.
- 5Thermo Fisher completed the acquisition of PPD on December 8, 2021 for $17.4 billion.
- 6Full-year 2022 COVID-19 testing revenue was $3.11 billion, down from $9.23 billion in 2021 (a ~66% decline); total 2022 revenue rose ~15% to $44.92 billion.
- 7CFO Stephen Williamson guided in May 2022 that full-year 2022 COVID testing revenue would total ~$2.1 billion, with an assumed 'endemic run-rate' of $100 million per quarter in H2 2022.
- 8Full-year 2023 revenue declined 5% to $42.86 billion; COVID-19 testing revenue fell to $330 million for the full year, with only $50 million in Q4 2023.